Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is a Bubble Building in Large-Cap Biotechs?

By Todd Campbell - Mar 18, 2014 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Big cap biotechs Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) have posted impressive gains in the past year that have all three trading at their highest valuation in years.

The iShares Nasdaq Biotechnology ETF ( IBB -2.26% ) has achieved an 81% return since February 2013, a return that trounces the S&P 500 index ETF's 26% return. By any measure, that's an astounding run, but does it signal a bubble has been built that's about to burst?

Let's take a look at three of the biggest biotech companies: Celgene ( CELG ), Biogen ( BIIB -2.65% ), and Amgen ( AMGN 0.96% ). All three have made cork-popping moves in the past year that suggest they might be due for a pause.

CELG Chart

CELG data by YCharts

Pricing in perfection?
At all three companies, the price to sales ratio -- which shows how much investors are paying for every dollar of revenue -- are hitting new five year highs. That enthusiasm is tied to each company rolling out new therapies that are driving revenue higher.

Celgene has successfully launched Abraxane, a cancer compound already approved as a treatment for breast, lung, and pancreatic cancers. Abraxane's sales jumped 90% in the past year to $202 million in the fourth quarter. Biogen rolled out Tecfidera last March as its first oral multiple sclerosis drug, and sales of the compound reached nearly $400 million last quarter.   And sales of Amgen's Prolia and Xgeva osteoporosis and cancer therapies were up 41% from last year to $522 million in the fourth quarter. 

AMGN PS Ratio (TTM) Chart

AMGN PS Ratio (TTM) data by YCharts

The success of those compounds have investors willing to pay up for earnings too. Biogen and Amgen's trailing 12 month price to earnings ratio are at their highest levels in five years, and Celgene's is at a three year high.

CELG PE Ratio (TTM) Chart

CELG P/E Ratio (TTM) data by YCharts

Looking into the future
The price to sales and price to earnings ratios suggest that investors are frothier today than they've been in years. However, both those measures are looking at how investors are valuing the companies on yesterday's results, not tomorrow's. Since markets are forward looking instruments, it may be helpful to instead consider how the three are valued using future sales and earnings estimates that take into consideration the potential for compounds like Abraxane, Tecfidera, and Prolia/Xgeva.

In the case of the companies' forward price to sales ratio, the measure is similar to the historical data, with investors paying more for future sales than they have in five years. But earnings are arguably more important given they're a better reflection of how efficiently companies operate and how likely companies will be to stay shareholder friendly. Unfortunately for bulls, all three companies' future price to earnings ratios are also lofty. To find a similar period where investors were willing to pay as much for future earnings you'd need to go back to the pre-recession peak. That suggests the potential for these fast-growing drugs may already be reflected by current share prices.

CELG PE Ratio (Forward) Chart

CELG P/E Ratio (Forward) data by YCharts

Fool-worthy final thoughts
Celgene, Biogen, and Amgen all appear to be a bit pricey based on where they've been in the past five years, but that doesn't necessarily mean they're in a bubble. No one can predict where the market will go in the short term. After all, markets have a tendency to surprise investors both on the way up and the way down.

That suggests investors shouldn't base their decision on whether to own these companies solely on their valuation, but also on their patent risks, FDA filings, and drugs making their way through their pipelines. If Celgene can successfully usher its potential psoriasis drug Apremilast through the FDA, Tecfidera can win over price hawks in Europe, and Amgen can win approval for a new therapy that could eventually alter how doctors treat high cholesterol, then share prices may not be as expensive as they appear. As a result, investors should not only consider the valuation risk, but also keep a close eye on regulatory filings and approvals before making a decision on whether to sell.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
CELG
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$200.80 (0.96%) $1.92
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$229.50 (-2.65%) $-6.24
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$150.74 (-2.26%) $-3.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.